Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma

BACKGROUND: Since the majority of melanomas eventually become resistant and progress, combining selective BRAF inhibitors (BRAFi) with immunotherapies has been proposed to achieve more durable treatment responses. Here, we explored the impact of selective BRAFi on the hosts' immune system. PATI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Schilling, B., Sondermann, W., Zhao, F., Griewank, K. G., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kähler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U., Schadendorf, D.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433519/
https://ncbi.nlm.nih.gov/pubmed/24504444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt587
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados